Stockscreener 앱 받기
7.5687
10.54%
0.6887
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpWhat's Next? - MarketBeat
Why Drug Developers That Utilize AI, Including SDGR and RXRX, Are Jumping - Yahoo Finance
Recursion Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RXRX) - MarketBeat
(RXRX) Investment Analysis - Stock Traders Daily
Recursion posts mid-stage data for lead asset - MSN
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - MSN
Avanza Fonder AB Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth - Insider Monkey
Blackrock’s 30 Most Important AI Stocks - Insider Monkey
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5%Still a Buy? - MarketBeat
Is Recursion Pharmaceuticals Stock a Buy? - MSN
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6%Should You Sell? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% HigherStill a Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8%What's Next? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.4% HigherTime to Buy? - MarketBeat
JPM25: Recursion $RXRXby AlbertRhymes with Haystack - substack.com
Why Recursion Pharmaceuticals Shares Are Dropping - TipRanks
Recursion Pharmaceuticals CEO sells shares worth $287,200 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells shares worth $287,200 - Investing.com India
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference - TipRanks
Recursion Pharmaceuticals: Betting Big On AI (NASDAQ:RXRX) - Seeking Alpha
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? - MSN
Long Term Trading Analysis for (RXRX) - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3%Time to Sell? - MarketBeat
Recursion: Investors Will Need To Be Patient (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.1% Following Analyst Downgrade - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA - Yahoo Finance
Recursion advances two cancer drug trials By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4%Should You Sell? - MarketBeat
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX) - MarketBeat
Recursion advances two cancer drug trials - Investing.com
RXRXRecursion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9%Time to Buy? - MarketBeat
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - Marketscreener.com
Recursion CEO to Present Pipeline and Platform Updates at JP Morgan Healthcare Conference - StockTitan
Iambic Therapeutics Taps Former Recursion CFO to Lead Financial Strategy and Development - StockTitan
0.81%
7.69%
자본화:
|
볼륨(24시간):